Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan

被引：0
|
作者：
Kentaro Sakamaki
Seitaro Yoshida
Yusuke Morita
Toshifumi Kamiura
Katsuhiro Iba
Naoyuki Ogawa
Hideki Suganami
Satoru Tsuchiya
Satoru Fukimbara
机构：
[1] The University of Tokyo,Department of Biostatistics and Bioinformatics
[2] Yokohama City University,Center for Data Science
[3] Japan Pharmaceutical Manufacturers Association,Data Science Expert Committee, Drug Evaluation Committee
[4] Chugai Pharmaceutical Co,Clinical Information & Intelligence Department
[5] Ltd,Clinical Data Science and Affairs
[6] Kyorin Pharmaceutical Co,Data Science Department
[7] Ltd,Department of Biometrics
[8] Nippon Shinyaku Co,Clinical Development Department
[9] Ltd,Clinical Data Science Department
[10] Otsuka Pharmaceutical Co,Data Science
[11] Ltd,Data Science
[12] Sanwa Kagaku Kenkyusho Co,undefined
[13] Ltd,undefined
[14] Kowa Company,undefined
[15] Ltd,undefined
[16] Sumitomo Dainippon Pharma Co,undefined
[17] Ltd,undefined
[18] Ono Pharmaceutical Co,undefined
[19] Ltd,undefined
来源：
Therapeutic Innovation & Regulatory Science | 2020年 / 54卷
关键词：
multiple endpoints; terminology; determination of endpoint; multiplicity adjustment; industry survey;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：528 / 533
页数：5
相关论文
共 50 条
  • [1] Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
    Sakamaki, Kentaro
    Yoshida, Seitaro
    Morita, Yusuke
    Kamiura, Toshifumi
    Iba, Katsuhiro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (03) : 528 - 533
  • [2] Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan
    Kentaro Sakamaki
    Yusuke Morita
    Katsuhiro Iba
    Toshifumi Kamiura
    Seitaro Yoshida
    Naoyuki Ogawa
    Hideki Suganami
    Satoru Tsuchiya
    Satoru Fukimbara
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1097 - 1105
  • [3] Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan
    Sakamaki, Kentaro
    Morita, Yusuke
    Iba, Katsuhiro
    Kamiura, Toshifumi
    Yoshida, Seitaro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1097 - 1105
  • [4] Some remaining challenges regarding multiple endpoints in clinical trials
    Snapinn, Steven
    STATISTICS IN MEDICINE, 2017, 36 (28) : 4441 - 4445
  • [5] How to deal with multiple endpoints in clinical trials
    Neuhaeuser, Markus
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2006, 20 (06) : 515 - 523
  • [6] Methodological challenges in the development of endpoints for myelofibrosis clinical trials
    Barosi, Giovanni
    Tefferi, Ayalew
    Gangat, Naseema
    Szuber, Natasha
    Rambaldi, Alessandro
    Odenike, Olatoyosi
    Kroeger, Nicolaus
    Gagelmann, Nico
    Talpaz, Moshe
    Kantarjian, Hagop
    Gale, Robert Peter
    LANCET HAEMATOLOGY, 2024, 11 (05): : e383 - e389
  • [7] Survey Results on Industry Practices and Challenges in Subgroup Analysis in Clinical Trials
    Mayer, Cristiana
    Lipkovich, Ilya
    Dmitrienko, Alex
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (04): : 272 - 282
  • [8] Procedures for testing multiple endpoints in clinical trials: An overview
    Wassmer, G
    Reitmeir, P
    Kieser, M
    Lehmacher, W
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1999, 82 (1-2) : 69 - 81
  • [9] Implementing optimal allocation in clinical trials with multiple endpoints
    Wang, Lu
    Chen, Yong
    Zhu, Hongjian
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2017, 182 : 88 - 99
  • [10] Some statistical methods for multiple endpoints in clinical trials
    Zhang, J
    Quan, H
    Ng, J
    Stepanavage, ME
    CONTROLLED CLINICAL TRIALS, 1997, 18 (03): : 204 - 221
12345